超基因医药 RARE
$15.43 −$0.14 (-0.90%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $15.43 0.00%
开盘$15.68
昨收$15.57
当日区间$15.12 – $15.97
成交量4.05M
市值$1.57B
市盈率（TTM）–
股息率–
RARE 相关新闻
匹配 Ultragenyx Pharmaceutical 或代码 RARE 的头条新闻，按最新排序。
- American Rare Earths Ltd: CSM Study Strengthens Foundation for U.S. REE Supply
- Ord Minnett Maintains LYNAS RARE EARTHS LTD(LYSCF.US) With Sell Rating, Cuts Target Price to $9.82 负面
- JX Advanced Metals: Notice Regarding the Agreement on a Joint Study for Entering the Rare Earth Refining Business with Tronox Co., Ltd.
- H.C. Wainwright Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Cuts Target Price to $25 负面
- UBS Maintains LYNAS RARE EARTHS LTD(LYSCF.US) With Buy Rating, Raises Target Price to $14.67 正面
- BofA Securities Maintains Ultragenyx Pharmaceutical(RARE.US) With Hold Rating, Maintains Target Price $20
- RBC Capital Downgrades Ultragenyx Pharmaceutical(RARE.US) to Hold Rating, Cuts Target Price to $19 负面
- Rare Element Resources Ltd. | 3: Initial statement of beneficial ownership of securities- Bilant Josef
- CSL Strikes US$1.6 Billion Licensing Deal for Rare Disease Drug | ASX:CSL
- Mobix Labs Merger Partner Special Project Delivery To Combine With U.S. Rare Earth Company Winner Water Services; Terms Not Disclosed
- Ord Minnett Upgrades LYNAS RARE EARTHS LTD(LYSCF.US) to Buy Rating, Raises Target Price to $9.76 正面
- Bond Selloff Is Opening up Rare Opportunities for Investors. Here Is Where to Look, Says Major Bank. 负面
- Lynas Rare Earths Price Target Cut 10% to A$18.00/Share by Jefferies 负面
- Shionogi: Shionogi Continues Rare Disease Expansion With Planned Acquisition of IntraBio Inc. 正面
- Goldman Sachs Maintains LYNAS RARE EARTHS LTD(LYSCF.US) With Buy Rating
暂无评论——快来第一个聊聊 RARE。